# Pelthos Therapeutics Inc. (PTHS)

> Source: Nexqual · https://nexqual.com/PTHS · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Pelthos Therapeutics Inc. (PTHS), nexqual.com/PTHS" · informational, not investment advice.

**Price:** USD 20.26 (+0.05% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 20.25 · day 20.15–20.81 · 52w 18.19–37.5 · market cap $77.6M · ASE

## Key facts
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 51.71 (range 40–64).
- Total return with dividends: 1Y -28.9% vs S&P 500 +18.1%; 5Y -57.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -3.06, revenue estimate $17.6M.

## Analysts
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 51.71 (low 40, high 64).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Lake Street | Target lowered | Buy | $50 → $40 |
| 2026-08-14 | Oppenheimer | Target lowered | Outperform | $66 → $64 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2024-02-12) |
|---|---|---|
| Total return | -28.9% | -57.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -29.0% | -27.6% |
| Volatility (annualized) | 75.0% | 113.6% |
| Max drawdown | -51.4% (Nov 2025→Feb 2026) | -88.2% (Feb 2024→Oct 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/PTHS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt